McKesson's $403B Machine: How the Largest Drug Distributor Is Quietly Building an AI-Powered Oncology Empire

McKesson posted $403.4B in FY2026 revenue — up 12% YoY — but the real story is the Oncology & Multispecialty segment growing 31% and delivering disproportionate profit. The company is simultaneously carving out its Medical-Surgical unit for a 2027 IPO while buying back shares at an extraordinary pace.

MCK · Health Care · July 09, 2026

S&P 500 Position

Within S&P 500 Health Care, McKesson is the dominant distributor. Its $96B market cap places it well above Cardinal Health (~$30-35B range historically) and in the same tier as Cencora. The Big Three distributors have dramatically outperformed the S&P 500 Health Care Index — delivering an average 45% gain since early 2023 versus 8% for the broader health care index. McKesson's premium valuation reflects the oncology/technology mix shift that its peers lack at comparable scale.

Index Weight: Data unavailable | Rank: Approximately top 50-60 in S&P 500 by market capitalization (~$96B)

Company Overview

McKesson operates the largest pharmaceutical distribution network in North America, moving roughly one-third of all medications through 50+ distribution centers. Together with Cencora (formerly AmerisourceBergen) and Cardinal Health, McKesson controls approximately 95% of the U.S. drug distribution market — a structural oligopoly that generates immense cash flow on razor-thin margins. McKesson is the clear revenue leader of the Big Three, with FY2026 consolidated revenue of $403.4 billion dwarfing Cencora's $294 billion. The company's strategic pivot centers on two higher-margin growth vectors: oncology services and prescription technology. The Oncology & Multispecialty segment — anchored by The US Oncology Network, one of the largest community-based oncology platforms in the country — grew revenue 31% in FY2026 and delivered 53% operating profit growth. CoverMyMeds, McKesson's prior authorization and medication access software platform, powers the Prescription Technology Solutions segment and generated $1.1 billion in adjusted operating profit on just $5.8 billion in revenue — a margin profile fundamentally different from the core distribution business. Meanwhile, McKesson is structurally reshaping its portfolio. Apollo Global invested $1.25 billion for a ~13% stake in the Medical-Surgical Solutions business at a $13 billion valuation, and management has targeted a second-half 2027 IPO for that unit. The aggressive share buyback program — $23 billion returned since fiscal 2020 — has driven stockholders' equity deeply negative at -$2.2 billion, a deliberate capital structure choice that has compressed share count and turbocharged per-share earnings growth to an 18% CAGR.

Products & Revenue

McKesson reorganized into four reportable segments starting in Q2 FY2026. The business is overwhelmingly driven by North American Pharmaceutical distribution, which accounts for 83% of revenue but operates on thin margins characteristic of wholesale drug distribution. The high-margin action sits in Oncology & Multispecialty and Prescription Technology Solutions, which together represent only ~13% of revenue but contribute roughly $2.5 billion of the ~$6 billion in total adjusted segment operating profit — a disproportionate share that explains management's strategic emphasis on these units.

North American Pharmaceutical (83.5%): Wholesale distribution of branded, generic, specialty, and biosimilar pharmaceuticals to retail pharmacies (including CVS at 24% of total revenue), hospitals, and health systems across North America. Revenue grew 11% YoY to $336.7B; adjusted segment operating profit was $3.5B (up 10%).

Oncology & Multispecialty (12.0%): Operates The US Oncology Network (community oncology practices), specialty drug distribution, GPO services, and clinical research for oncology and other specialties. Revenue of $48.4B grew 31% YoY; adjusted segment operating profit hit $1.4B (up 53%), making it the fastest-growing segment by every measure.

Medical-Surgical Solutions (2.9%): Distributes medical supplies, equipment, and lab products to physician offices, surgery centers, and extended care facilities. Revenue of $11.5B grew just 1% YoY. Being carved out for a 2027 IPO following Apollo's $1.25B minority investment at a $13B enterprise valuation.

Prescription Technology Solutions (1.4%): Software and data platform (anchored by CoverMyMeds) that automates prior authorization, medication affordability, and specialty enrollment workflows. Revenue of $5.8B grew 11% YoY; adjusted operating profit of $1.1B implies margins roughly 6x those of the distribution business. Supported 3.4 million patients in annual verification season and helped save ~$10B on brand/specialty medications.

Based on McKesson FY2026 10-K (fiscal year ended March 31, 2026) filed with the SEC. Segment structure implemented Q2 FY2026.

Leadership

Brian S. Tyler

CEO since 2019. Tyler became CEO in April 2019 after more than 25 years at McKesson, rising through the pharmaceutical distribution operations. He was elevated to Chair of the Board effective May 1, 2026. Under his leadership, McKesson has executed the oncology-centric strategy, the MMS carve-out, and over $23 billion in capital returns.

Kenny Cheung, Executive Vice President & CFO: Joined McKesson effective May 29, 2026, succeeding longtime CFO Britt Vitalone. Previously EVP and CFO at Sysco, where he oversaw large-scale distribution finance operations — directly relevant experience for McKesson's logistics-intensive model.

Francisco Fraga, EVP, Chief Information Officer & Chief Technology Officer: Leads McKesson's technology infrastructure and digital transformation since 2023. Previously CTO/CIO at Campbell Soup Company. Oversees the AI-driven supply chain planning platform and enterprise-wide digital enablement programs.

Thomas L. Rodgers, EVP, Chief Strategy Officer & Chief Business Development Officer: Architect of McKesson's M&A and portfolio strategy since 2020, including the MMS carve-out, Apollo partnership, and CoverMyMeds bolt-on acquisitions (RxLightning, FastAuth).

Dominic J. Caruso, Lead Independent Director: Elected Lead Independent Director effective May 1, 2026, concurrent with Tyler becoming Chair. Previously CFO of Johnson & Johnson — brings deep healthcare finance governance experience to balance the combined Chair/CEO role.

The AI Angle

AI As Operational Accelerant, Not Revenue Product

McKesson's AI strategy is operationally focused rather than product-centric. The flagship deployment is an AI-driven planning system rolled out across its entire North American distribution network that unifies demand forecasting, supply allocation, inventory optimization, and logistics operations into a single integrated environment. For a company moving one-third of all U.S. pharmaceuticals through 50+ distribution centers, even marginal efficiency gains at this scale translate to significant cost savings. The system represents a shift from reactive batch-planning to real-time decision-making — critical when distributing temperature-sensitive biologics and controlled substances with strict regulatory timelines. The measurable results are concrete: AI-powered virtual assistants now deflect over 40,000 customer calls per month, generating $2.2 million in annualized savings. In oncology, McKesson has processed more than 150 million document components using Microsoft Azure OpenAI services, and ambient scribe technology is now used by over 1,900 providers in The US Oncology Network — reducing clinical documentation burden in a specialty where physician burnout directly threatens network retention. One process that previously took 17 days has been compressed to 3 minutes. McKesson's approach is firmly buy-and-integrate rather than build-from-scratch. Key partnerships include Microsoft for Azure OpenAI services (oncology data processing), Genpact for finance operations automation, and Five9 for contact center AI. McKesson Ventures has made strategic investments in companies like Komodo Health. Internally, the company launched an enterprise-wide digital enablement and AI mindset training program to drive adoption across its workforce — a recognition that AI deployment in regulated healthcare distribution requires cultural change, not just technical implementation. The competitive risk is that AI in distribution is table stakes: Cencora and Cardinal Health are pursuing similar operational AI initiatives. McKesson's differentiation lies in the oncology data moat — The US Oncology Network generates proprietary clinical data at scale that feeds AI-driven clinical decision support and research workflows. CoverMyMeds' prior authorization automation, expanded in March 2026 with integrated specialty access workflows for oncology and ophthalmology, represents the closest thing McKesson has to an AI-powered software product with direct revenue implications.

Financial Snapshot

Revenue (TTM): $403.4B — FY2026 (ended March 31, 2026) | Net Income: $4.8B net income (GAAP); adjusted EPS $39.11 (up 18% YoY)

Margins: Net margin 1.2% (characteristic of distribution); EBIT $5.1B implies operating margin ~1.3%. Prescription Technology Solutions runs at approximately 19% adjusted operating margins — the margin mix-shift story in a single number.

McKesson's balance sheet is a deliberate financial engineering construct. The company has returned $23 billion to shareholders since fiscal 2020, compressing share count aggressively enough to drive 18% adjusted EPS growth on 12% revenue growth. FY2027 guidance of $43.80-$44.60 adjusted EPS implies 12-14% further growth. Free cash flow guidance of $4.5-$4.9 billion against ~$5 billion in planned buybacks means the company will continue funding repurchases partly with debt issuance — a strategy that works as long as the spread between cost of debt and earnings yield remains favorable. The $7.7 billion remaining buyback authorization and newly structured MMS financing ($1B term loan, $1B revolver, up to $2.25B additional term loans) add complexity but also flexibility.

1-Year Performance

$792.81, up 9.5% YoY — modest relative to the company's 18% EPS growth, suggesting some multiple compression or market caution around the MMS IPO execution risk.

The stock pulled back from what appears to have been a ~$940 level in March 2026 to the current $793. Q4 FY2026 earnings in May showed a beat on EPS ($11.69 vs. $11.57 consensus) but a meaningful revenue miss ($92.3B vs. $101.2B expected), driven by Medical-Surgical weakness. The strong FY2027 guidance — particularly the $5 billion buyback commitment — provides a floor, but investors are pricing in uncertainty around the MMS carve-out and ongoing opioid litigation overhang ($5.7B in remaining liabilities).

Recent News

Fun Fact: CoverMyMeds, which McKesson acquired for $1.1 billion in 2017, operates a five-facility pharmacy dispensing network where prescriptions are filled using robotics, machine vision, RFID tracking, and precision scales — essentially a lights-out pharmaceutical fulfillment operation. The platform processes prior authorization workflows that helped patients save approximately $10 billion on brand and specialty medications in FY2026 alone, making it one of the largest invisible cost-reduction engines in American healthcare that most patients never know exists.